We read with interest the recent letter by Schmitz and colleagues 1 about the differences between cell lines in apoptosis signaling induced by Fas (APO-1/CD95) ligation. We have recently obtained results 2 that challenge the conclusions described in their letter.
The key signaling intermediate is the adapter molecule, FADD/MORT1, which recruits the initiator caspase, caspase-8, to promote its auto-activation. Once activated, caspase-8 can activate downstream effector caspases, such as caspase-3, leading to the demise of the cell. Such a model for Fas-induced apoptosis signaling is confirmed by analyses of mice lacking critical components of this pathway. Cells lacking FADD or caspase-8 function are as resistant to Fas-transduced apoptosis as those from Fas-deficient lpr mice. 4 ± 8 In contrast, cells lacking Apaf-1 or caspase-9, critical components of the so-called mitochondrial apoptosis signaling pathway' are normally sensitive to Fas ligation. 9 ± 12 Based on in vitro studies with immortalized cell lines, Scaffidi and colleagues 13 proposed the existence of a second apoptosis signaling pathway induced by Fas. This pathway to apoptosis, utilized by the so-called type II cells, is characterized by almost complete absence of DISC formation induced by Fas and can be inhibited by prosurvival Bcl-2 proteins. It has been proposed that this pathway requires caspase-8-mediated cleavage and activation of the BH3-only protein Bid. 14 ± 16 In support of this interpretation, this pathway is apparently utilized in hepatocytes in vivo since overexpression of Bcl-2 in the liver 17 or absence of Bid 18 can protect mice against the lethal effects of injection with anti-Fas antibodies.
In contrast, when we used aggregated recombinant FasL or membrane-bound FasL, we have not detected any protection by Bcl-2 or by Bcl-x L in vivo or in vitro. We believe that the membrane bound FasL is the physiological form of the ligand that induces killing in vivo since trimerization of Fas alone is insufficient for this. 19, 20 Importantly, leucine zipper tagged FasL causes trimerization 21 and not extensive aggregation of the receptor that is induced by FLAG-tagged FasL or membrane-bound FasL used in our experiments. When Fas is extensively aggregated, Bcl-2 did not afford any protection, in lymphocytes, granulocytes, hepatocytes or in pancreatic islet b-cells. 2, 22 Furthermore, when Fas is extensively aggregated by cross-linking anti-Fas antibodies or trimeric FasL, there was no difference in the translocation of FADD or caspase-8 to the plasma membrane between the socalled type I and II cells. 2 A difference between these cells was only observed when anti-Fas antibodies alone were used.
How might these differences be explained? Firstly, the experimental settings may be significantly different. Tissue culture cell lines do not reliably reproduce the physiological situation since many such lines harbor transforming mutations in genes that are critical for cell death regulation. Such mutations may therefore compromise the results of cell survival assays obtained with such cell lines. Furthermore, since killing by Fas requires extensive receptor aggregation, 19, 20 the experiments should be designed to reproduce this. As anti-Fas antibodies may not reliably mimic the physiological ligand, 2 we should be careful about drawing biological conclusions when such reagents are used. For example, Bcl-2 transgenic 17 or Bid-deficient mice 18 were only injected with intermediate doses of anti-Fas antibodies, not FasL. Indeed, it is remarkable that these mice were only partially protected from the lethal effects of injecting anti-Fas antibodies, in striking contrast to complete protection afforded when Fas is mutated. 23, 24 It is also worth noting that these animals do not develop liver hyperplasia unlike mice lacking Fas. 23 It is also important to distinguish between those steps that are essential for all killing (FADD, caspase-8) and those that are primarily amplification steps (Bid cleavage) which may be inhibitable by Bcl-2. 25 An attractive explanation for the differences observed is that such an amplification step may be utilized in some (e.g. hepatocytes) but not by other cell types (e.g. lymphocytes). The data obtained with Bcl-2 transgenic or Biddeficient mice would be consistent with such a model since these mutations delay the mortality caused by intermediate doses of anti-Fas antibodies, but do not protect the animals. An alternative possibility is that FasL, and possibly anti-Fas antibodies, kill hepatocytes indirectly. This killing may be mediated by cytokines such as IFN-g, a cytotoxic agent that kills by a Bcl-2-inhibitable mechanism. 26 We agree with Schmitz et al 1 that more experiments need to be performed, but we emphasize that these studies should be performed whenever possible in physiological settings and using reagents that reliably mimic the endogenous signals. Such experiments will allow us to draw correct conclusions about the biological mechanisms of cell death induced by Fas.
